articleThe Lancet OncologyDec 5, 2016GREEN OA

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

MDMatthew D. HellmannNANaiyer A. RizviJWJonathan W. GoldmanSGScott GettingerHBHossein Borghaei

Memorial Sloan Kettering Cancer Center · UCLA Jonsson Comprehensive Cancer Center · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

958
total citations
FWCI
66.81
Percentile
100%
References
36
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Nivolumab
  • Ipilimumab
  • Medicine
  • Tolerability
  • Internal medicine
  • Lung cancer
  • Oncology
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding